Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma has announced the results of Phase 2 placebo-controlled study conducted by AstraZeneca to compare the efficacy of selumetinib in combination with docetaxel in patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Subscribe to our email newsletter
Selumetinib, a small molecule MEK inhibitor, is an anti-cancer drug in Phase 2 development in a range of tumors. It was licensed from Array to AstraZeneca.
The study demonstrated a rise in survival rate in patients who were given selumetinib in combination with docetaxel versus docetaxel alone.
The secondary endpoints of progression-free survival, objective response rate, and alive and progression-free at 6 months showed improvement in favor of selumetinib in combination with docetaxel versus docetaxel alone.
AstraZeneca is also set to complete Phase 2 trial with selumetinib in combination with dacarbazine.